Abingdon Health Ltd, a York, UK-based specialist medical diagnostics company, raised £3m in funding.
The round was led by existing investor Imperial Innovations.
The company intends to use the funds to support the commercialization of its recently launched products in the area of multiple myeloma testing.
Led by Chris Yates, CEO of Abingdon Health is commercializing Seralite®‐ FLC Serum and Seralite®– FLC Urine. These assays allow for the rapid quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) as an aid to the diagnosis and management of multiple myeloma.
On 27 June 2016, the company announced it had entered into a multi-year, exclusive, global distribution agreement with Sebia – the world leader in medical diagnostics by capillary electrophoresis – for Seralite®-FLC Serum.